Indoco Remedies has received approval from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its new solid dosages manufacturing facility in Baddi, Himachal Pradesh (Baddi III unit). The inspection was held from October 16 to October 18, 2018. The facility is spread over an area of 18000 sqm, with manufacturing capacity of 4.3 billion tablets and 50 million capsules p.a.
This is the first Regulatory inspection for the plant, which was acquired in 2016. The outcome of this inspection is positive and is a testimony that Indoco maintains global quality standards and follows strict GMP guidelines. The facility will cater mainly to the European markets.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
